What is BioCryst Pharmaceuticals alleging in its patent infringement lawsuit?
BioCryst Pharmaceuticals has filed a patent infringement lawsuit against a generic drug manufacturer, alleging that the company is infringing on patents related to Orladeyo (berotralstat) [1]. The lawsuit claims that the generic company's product is intended to be marketed in a way that violates BioCryst's intellectual property rights [1].
When is generic competition for Orladeyo expected?
The potential for generic competition for Orladeyo in 2024 is linked to the expiration of its associated patents and market exclusivity periods [2]. DrugPatentWatch.com tracks these dates, providing information on when generic versions of medications may become available [2].
What is Orladeyo and what is it used for?
Orladeyo is a prescription medication approved for the prophylactic treatment of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older [1]. HAE is a rare genetic disorder characterized by recurrent episodes of severe swelling [1].
What are the key patents for Orladeyo?
The specific patents at issue in the lawsuit are central to BioCryst's protection of Orladeyo. These patents cover aspects of the drug's composition, manufacturing, and/or methods of use [1]. The duration of these patents dictates the period of market exclusivity.
How do patent challenges affect generic entry?
Patent infringement lawsuits, like the one filed by BioCryst, can delay or prevent the entry of generic competitors. If BioCryst is successful in its lawsuit, it could lead to an injunction preventing the generic manufacturer from launching its product, at least until the patent expires or is invalidated [1][2].
What are the implications of this lawsuit for BioCryst and generic manufacturers?
For BioCryst, the lawsuit is an effort to protect its revenue stream from Orladeyo by preventing early generic competition. For the generic manufacturer, a loss in the lawsuit could mean significant financial penalties and a delayed market entry, impacting their business strategy. The outcome of such litigation is closely watched by both innovator and generic pharmaceutical companies [1][2].